What's Happening?
In a recent episode of Greenberg Traurig's Big Law Redefined Podcast, experts discussed the challenges and strategies for entering the European health care market. The conversation, led by Charles Dunham with colleagues Dr. Christian Rybak and Julian
Bartholomä, focused on the EU Medical Device Regulation and new AI rules, which present significant challenges for digital health, MedTech, and life sciences companies. The discussion highlighted the importance of obtaining CE marking and navigating reimbursement across the EU's 27 member states. The experts emphasized the need for companies to align their regulatory, reimbursement, and commercial strategies from the outset to succeed in the European market.
Why It's Important?
The insights provided in the podcast are crucial for U.S. companies looking to expand into the European health care market, which is characterized by a complex regulatory environment. Understanding the EU's conformity-based system, as opposed to the FDA's centralized model, is essential for compliance and market entry. The discussion underscores the importance of integrating reimbursement strategies into clinical development, as differing evidence standards can impact market access. This knowledge is vital for companies aiming to navigate the regulatory landscape effectively, avoid legal pitfalls, and achieve commercial success in Europe.
